Ocugen's OCU400 heads toward a 2026 EMA filing decision in retinitis pigmentosa
Ocugen says its gene therapy remains on track for EMA marketing authorization this year, even as the Phase 3 trial backing the filing pushed its completion date out to 2027.
Executive Summary
- Ocugen is working toward an EMA marketing authorization decision in 2026 for its Phase 3 gene therapy in retinitis pigmentosa, a decision the company has said would be based on a mutation-agnostic approach that could reach patients regardless of their specific genetic mutation.
- The European regulator has already cleared the procedural path to file, granting the therapy eligibility for a centralized filing and advanced-therapy classification, and European and U.S. regulators have each granted status typically reserved for therapies addressing significant unmet need.
- The pivotal trial underpinning that filing has had its completion timeline pushed back twice in the past year, raising the question of whether the confirmatory evidence will be finalized on the schedule the EMA decision assumes.
- The therapy is the only Phase 3 program of its kind targeting this gene in this disease, with a nearby earlier-stage trial from the same sponsor as its closest comparator, in an indication where no other program has advanced this far on the same genetic target.
The decision ahead
Ocugen says OCU400 remains on track for a targeted EMA marketing authorization application (MAA) approval in retinitis pigmentosa in 2026, according to the company's own guidance. The therapy is a gene therapy candidate targeting the RHO gene, designed to work regardless of which mutation causes a patient's retinitis pigmentosa. The registered trial behind the filing, NCT06388200, is a Phase 3, randomized, single-masked study enrolling 150 patients across four arms in the United States. Press Release+1Press ReleaseA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the EMA has already cleared
The regulatory path to this decision has cleared several procedural steps. The EMA's Committee for Advanced Therapies gave OCU400 a positive opinion for advanced-therapy classification, and the agency separately granted eligibility to submit a centralized MAA through the accelerated procedure. The FDA has granted OCU400 Regenerative Medicine Advanced Therapy designation and orphan drug designation in the U.S., and the EU has granted orphan designation covering retinitis pigmentosa and Leber congenital amaurosis. These designations signal that regulators view the unmet need as substantial; they do not by themselves determine whether the pending application clears. Press Release
The trial behind the filing
The Phase 3 trial's operational history complicates the picture. Its primary completion date was originally set for June 30, 2025, then pushed to December 31, 2026, and most recently to February 12, 2027. The trial also moved to Active, not recruiting status in February 2026, and its target enrollment was revised from 150 to 140 patients around the same time, a change within the routine range for a trial of this size. The completion-date slippage, not the enrollment change, is what bears on whether final Phase 3 data will be in hand to support a 2026 EMA decision as currently guided. NCT06388200A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200
Prior clinical signal
The strongest clinical signal to date comes from Ocugen's earlier-stage program. The company has reported long-term, roughly three-year follow-up from its Phase 1/2 cohort of 22 patients, describing an approximately two-line gain in low-luminance visual acuity with a tolerability profile it characterized as favorable. That data comes from an open-label, uncontrolled cohort, which makes it hypothesis-generating for the mutation-agnostic approach rather than a substitute for the randomized Phase 3 comparison against an untreated control arm that the pending EMA decision will ultimately need to rest on. NCT06388200A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200
Competitive position
OCU400's Phase 3 trial is the only industry-sponsored Phase 3 study targeting RHO in retinitis pigmentosa; the closest comparator is Ocugen's own earlier-stage OCU400 program in the same indication. Other gene therapy programs in retinitis pigmentosa target different genes, including RPGR-targeted therapies from Janssen and Beacon Therapeutics and a rhodopsin-directed program from Octant, none of which share OCU400's specific target or its mutation-agnostic design. No prior RHO-directed program has reached a regulatory decision in this indication, so the EMA action would be a first test of whether this genetic approach can clear a European filing.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.